VIDEO: Data suggest HIPEC safe for patients with ovarian cancer and underlying kidney disease

In this video, Robert DeBernardo, MD, discusses his research on hyperthermic intraperitoneal chemotherapy among patients with ovarian cancer and underlying kidney disease, which he presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

DeBernardo, section head of the department of obstetrics and gynecology and Women’s Health Institute at Cleveland Clinic, explains that hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin appears safe in this patient population.

“What we’ve shown in our data are that [among] people who have underlying kidney disease, it’s safe to give HIPEC with cisplatin, which is the drug that causes that kidney injury,” DeBernardo said. “We’ve shown outcomes don’t change: We don’t make their renal failure worse in the short- or long-term.”